- 主辦 / 主持人
- 台灣肺癌學會
- 積分
- B類 1 分
- 分類
- 未分類
- 聯絡人
- 台灣肺癌學會 02-28289897
- 活動日期
- 2021-02-23 (二) 12:30 ~ 13:30
- 地點
- 視訊會議
- 說明
- Lung cancer imposes a major disease burden on the world. It remains the most commonly diagnosed cancer and the greatest cause of cancer-related death. In non-small-cell lung cancer (NSCLC), epidermal growth factor receptor (EGFR) exon 19 deletion (Del19) and exon 21 Leu858Arg substitution (L858R), which account for 90% of all EGFR mutations, are associated with favorable outcomes in patients treated with EGFR-tyrosine kinase inhibitors (TKIs). Many retrospective and prospective studies, as well as meta-analyses, that have studied NSCLC patients with various lines of EGFR-TKI treatment have demonstrated longer progression-free survival (PFS) and occasionally more favorable overall survival (OS) in those with Del19 than in those with the L858R or other mutations. Therefore, there are differences in the mechanisms and efficacy between patients with these common EGFR mutations. In this lecture, Prof. Barbara Melosky will share the clinical benefit of TKI in advanced NSCLC, and explored the survival differences between two common mutation subtypes.
摘要檔案: Del19 and L858R EGFR mutations_abstract.docx
2021-02-23 視訊會議
| 時間 | 主題 | |
|---|---|---|
| 沒有資料 | ||